These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 24787291)

  • 1. Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications.
    Diaz-Montero CM; Finke J; Montero AJ
    Semin Oncol; 2014 Apr; 41(2):174-84. PubMed ID: 24787291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
    De Cicco P; Ercolano G; Ianaro A
    Front Immunol; 2020; 11():1680. PubMed ID: 32849585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives.
    Mortezaee K
    Life Sci; 2021 Jul; 277():119627. PubMed ID: 34004256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the origin of myeloid-derived suppressor cells.
    Millrud CR; Bergenfelz C; Leandersson K
    Oncotarget; 2017 Jan; 8(2):3649-3665. PubMed ID: 27690299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.
    Groth C; Hu X; Weber R; Fleming V; Altevogt P; Utikal J; Umansky V
    Br J Cancer; 2019 Jan; 120(1):16-25. PubMed ID: 30413826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.
    Hossain DM; Pal SK; Moreira D; Duttagupta P; Zhang Q; Won H; Jones J; D'Apuzzo M; Forman S; Kortylewski M
    Clin Cancer Res; 2015 Aug; 21(16):3771-82. PubMed ID: 25967142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid-derived suppressor cells in cancer: recent progress and prospects.
    Khaled YS; Ammori BJ; Elkord E
    Immunol Cell Biol; 2013 Sep; 91(8):493-502. PubMed ID: 23797066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid-Derived Suppressor Cells and Therapeutic Strategies in Cancer.
    Katoh H; Watanabe M
    Mediators Inflamm; 2015; 2015():159269. PubMed ID: 26078490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid-Derived Suppressor Cells in Solid Tumors.
    Ma T; Renz BW; Ilmer M; Koch D; Yang Y; Werner J; Bazhin AV
    Cells; 2022 Jan; 11(2):. PubMed ID: 35053426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.
    Safarzadeh E; Hashemzadeh S; Duijf PHG; Mansoori B; Khaze V; Mohammadi A; Kazemi T; Yousefi M; Asadi M; Mohammadi H; Babaie F; Baradaran B
    J Cell Physiol; 2019 Apr; 234(4):3515-3525. PubMed ID: 30362521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IRF7 regulates the development of granulocytic myeloid-derived suppressor cells through S100A9 transrepression in cancer.
    Yang Q; Li X; Chen H; Cao Y; Xiao Q; He Y; Wei J; Zhou J
    Oncogene; 2017 May; 36(21):2969-2980. PubMed ID: 28092673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy.
    Krishnamoorthy M; Gerhardt L; Maleki Vareki S
    Cells; 2021 May; 10(5):. PubMed ID: 34065010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of T cells by myeloid-derived suppressor cells in cancer.
    Chen J; Ye Y; Liu P; Yu W; Wei F; Li H; Yu J
    Hum Immunol; 2017 Feb; 78(2):113-119. PubMed ID: 27939507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
    Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
    Front Immunol; 2020; 11():585214. PubMed ID: 33613512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients.
    Jordan KR; Kapoor P; Spongberg E; Tobin RP; Gao D; Borges VF; McCarter MD
    Cancer Immunol Immunother; 2017 Apr; 66(4):503-513. PubMed ID: 28108766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.
    Li K; Shi H; Zhang B; Ou X; Ma Q; Chen Y; Shu P; Li D; Wang Y
    Signal Transduct Target Ther; 2021 Oct; 6(1):362. PubMed ID: 34620838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Circulating Myeloid Suppressor Cells and Their Role in Tumour Immunology].
    Pilatova K; Budinská E; Bensciková B; Nenutil R; Šefr R; Fedorová L; Hanáková B; Brychtová V; Zdražilová Dubská L
    Klin Onkol; 2017; 30(Supplementum1):166-169. PubMed ID: 28471197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulocytic Myeloid-Derived Suppressor Cells as Negative Regulators of Anticancer Immunity.
    Kramer ED; Abrams SI
    Front Immunol; 2020; 11():1963. PubMed ID: 32983128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future Perspectives.
    Ibáñez-Vea M; Zuazo M; Gato M; Arasanz H; Fernández-Hinojal G; Escors D; Kochan G
    Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):113-123. PubMed ID: 29032490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
    Kamran N; Chandran M; Lowenstein PR; Castro MG
    Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.